Vertex Pharmaceuticals Incorporated Announced That The U.S. Food And Drug Administration (Fda) Has Cleared The Investigational New Drug Application (Ind) For Vx-264, A Stem Cell-Derived, Fully Differentiated Pancreatic Islet Cell Therapy Encapsulated Into A Vertex-Developed, Immunoprotective Device With The Potential To Treat Type 1 Diabetes (T1D). The Vx-264 Programme Does Not Require The Use Of Immunosuppression, Which May Broaden The Population Of People With T1D That This Investigational Therapy Could Reach.Vx-264 Is An Investigational Cell Therapy In Which Allogeneic Human Stem Cell-Derived Islets Are Encapsulated In A Channel Array Device Designed To Shield The Cells From The Body
